PGENPRECIGEN, INC.
Pharmaceutical Preparations
- Revenue
- $10M
- 147% YoY
- Operating margin
- -1141.1%
- 67% YoY
- EBITDA
- −$107M
- 18% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $78M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired112% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear9% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $14M | $27M | $6M | $4M | $10M | 147% |
| Operating income | — | — | −$100M | −$135M | −$111M | 18% |
| Net income | −$92M | $28M | −$96M | −$126M | −$251M | 99% |
| Operating cash flow | −$56M | −$65M | −$67M | −$68M | −$88M | 29% |
| Capex | $7M | $5M | $2M | $9M | $2M | 77% |
| Stock-based comp | $14M | $10M | $10M | $9M | $11M | 15% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $5M | $19M | 41 | 125 |
| FY2024 | $5M | $5M | 20 | 114 |
| FY2023 | $4M | $4M | 24 | 115 |
| FY2022 | $3M | −$1M | 28 | 111 |
| FY2021 | $3M | −$16M | 68 | 125 |